FIELD: pharmacology.
SUBSTANCE: group of inventions refers to application of an active ingredient to obtain a drug to regulate the glucose level in blood, while the active ingredient is selected from the compound of formula (1): 
Glu: glucose, Rha: Rhamnose or its pharmaceutically acceptable salts, as well as to treatment of a diabetes mellites of type I, where the active ingredient is selected from the compound (2): 
Rha: Rhamnose or its pharmaceutically acceptable salts.
EFFECT: invention implementation allows to expand the arsenal of drugs for regulation of blood sugar level and treatment of type I diabetes.
18 cl, 11 dwg, 9 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| USING EXTRACT OF CISTANCHE TUBULOSA IN PREPARING MEDICINAL PRODUCTS OR FOOD PRODUCTS FOR EYE CELLS PROTECTION | 2015 |
|
RU2688939C2 |
| NEW APPLICATION OF LIVER X RECEPTOR AGONISTS | 2006 |
|
RU2417078C2 |
| USING TISSUE FACTOR INHIBITOR OR ANTAGONIST | 2003 |
|
RU2315621C2 |
| PIM-3 KINASE AS TARGET FOR DIABETES MELLITUS TYPE 2 | 2003 |
|
RU2316598C2 |
| COMPOSITIONS FOR DRUG INTRODUCTION | 2009 |
|
RU2554814C2 |
| COMPOSITIONS AND METHODS FOR USING PEPTIDES OF NEEGENIOSIS ISLANDS AND ANALOGUES THEREOF | 2014 |
|
RU2685958C2 |
| METHOD FOR PREVENTING GLP-1 SIDE EFFECTS | 2008 |
|
RU2474415C2 |
| METHOD FOR TREATING NIDDM BY RXR AGONISTS | 1996 |
|
RU2191007C2 |
| ACTIVE SUBSTANCE DELIVERY | 2008 |
|
RU2467741C2 |
| CANCER MODELS AND CORRESPONDING METHODS | 2014 |
|
RU2707531C2 |
